Mineralys Therapeutics (MLYS) Other financing activities (2022 - 2026)

Mineralys Therapeutics has reported Other financing activities for 4 years, with the latest figure at $4.1 million in Q1 2026.

• Quarterly Other financing activities rose 3196.75% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.9 million (up 103.4% YoY) and the FY2024 annual result came in at $221000.0, changed N/A from the prior year.
• Other financing activities rose to $4.1 million in Q1 2026 per MLYS's latest filing, from -$142000.0 in the prior quarter.
• Over five years, Other financing activities peaked at $203.0 million in Q3 2023 and troughed at -$203.0 million in Q4 2023.
• A 4-year average of $388727.3 and a median of $83000.0 in 2024 frame the typical range for Other financing activities.
• The sharpest annual moves came in 2025 and 2026: Other financing activities slumped 271.08% in 2025, then soared 3196.75% in 2026.
• Over 4 years, Other financing activities stood at -$203.0 million in 2023, then jumped by 100.04% to $83000.0 in 2024, then plunged by 271.08% to -$142000.0 in 2025, then jumped by 2955.63% to $4.1 million in 2026.
• According to Business Quant data, Other financing activities over the past three periods registered $4.1 million, -$142000.0, and $142000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.